CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » NEWS

Oncology NEWS International. Vol. 17 No. 10
PEOPLE & PLACES 

Triathlon for an MPD cure

By Ruben A. Mesa, MD | October 1, 2008

ROCHESTER, Minnesota—On September 7 in Madison, cheered on by family and friends, I Photocompleted the Ford Ironman Wisconsin Triathlon (2.4 miles of swimming, 112 miles of cycling, and a marathon of 26.2 miles) in 14 hours and 34 minutes.

The 140.6-mile odyssey was the culmination of a multi-year journey of self-discovery and a year-long philanthropic effort to raise awareness for myeloproliferative disorders (MPDs).

In 2003, I had completed my fellowship in hematology and medical oncology at the Mayo Clinic, and found myself carrying 300 pounds on my 5-foot-9-inch frame. I was always a heavy man, but the demands of medical training had led to physical inactivity and further weight gain.

After years of taking care of patients with malignant diseases, the lessons they had taught me were finally sank in. These patients were facing challenging, and sometimes fatal, diseases with strength and courage. I saw people my own age with acute leukemia or MPDs willing to risk all their potential remaining days for just one hope for a cure.

Meanwhile, I was blessed with perfectly good health, but I was squandering it away. The future consequences of my lifestyle were clear: hypertension, diabetes, coronary disease and even death. On January 1, 2003 (yes, some New Year’s resolutions work), I vowed to honor the good health I was blessed with as a testament to my patients who were not as fortunate.

MPDs

Along with my colleague and mentor, Ayalew Tefferi, MD, I specialize in MPDs. Areas that I have worked in include efforts to better understand and quantify the symptomatic burdens of MPDs and investigating how physical activity might improve disease-related symptoms.

MPDs have seen an explosion of research advances since the discovery of the JAK2-V617F mutation in 2005. A host of additional pathogenetically linked mutations were subsequently identified. Key MPD breakthroughs have been followed by the rapid development of over a dozen potentially clinically active inhibitors of JAK2; several are now undergoing investigation in phase I and II clinical trials. Now is a crucial period for research funding to advance the therapy for patients who desperately need better treatments today.

I wanted to give back to my courageous patients by trying to raise awareness and crucial funds for research. I approached the two main advocacy foundations—MPD Foundation and the CMPD Education Foundation—and asked if I could have the honor of trying to raise funds and awareness funds on their behalf. We called the effort “TRIing for an MPD Cure.”

‘Legs of jelly’

Back in 2003, hard work, better nutrition, and joining the Mayo Clinic’s community program for learning how to run marathon medical training programs helped me lose 130 pounds.

I ran my first 5K road race in November of 2003. To date, I’ve completed 10 marathons in various U.S. cities. I also decided to try my hand at triathlons and, after 30 “practice” events, I confronted the king of all triathlons, the Ironman.

For the Madison event, a year of hard training—over 5,000 miles of cycling, 2,000 miles of running, and hundreds of miles of swimming—proved its worth on that sunny morning of the race. The 2.4-mile swim start with my 2,300 fellow racers was part contact sport and part swim.

The epic cycle ride consisted of 112 miles in a stiff west wind and an endless series of Midwestern hills. After a full day that started at 7 a.m., I still faced a full marathon by late afternoon.

With legs of jelly I stumbled out of the transition zone. I thought of my patients and their struggles, which grounded me in simplicity and ease. They gave me the strength to journey through those toughest miles. A final wave of energy and emotion welled up inside me as I sprinted through the finish to the embrace of my family.

“TRIing for an MPD Cure” raised over $12,000 for key MPD research efforts. I will continue to run and repay the debt I owe to my patients who taught me to cherish life and live it to the fullest.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Skin Lesions
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • Colorectal Lesions
  • New AUA Guidelines for Prostate Cancer Screening
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Genomics Studies Identify Testicular Cancer Risk Variants
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
Click here to subscribe to our newsletter


CancerNetwork on Facebook


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy